Resources from the same session
4884 - Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain
Presenter: Laura Chow
Session: Proffered Paper 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
2693 - Integrated Genomic and DNA Methylation Analyses of Non-Small Cell Lung Cancer Patients with Brain Metastases
Presenter: Yanjun Xu
Session: Proffered Paper 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
6256 - IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC
Presenter: David Spigel
Session: Proffered Paper 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
3570 - Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials
Presenter: Roy S. Herbst
Session: Proffered Paper 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
4311 - Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
Presenter: Luis Paz-Ares
Session: Proffered Paper 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Proffered Paper 1 - NSCLC, metastatic - Invited Discussant 1478O and 1479O
Presenter: Lizza Hendriks
Session: Proffered Paper 1 - NSCLC, metastatic
Resources:
Slides
Webcast